Third Quarter 2026
Filed Nov 5, 2026Lipocine reported third-quarter total revenues of $ 2,290,072, led by $ 2,100,000 of license revenue, and a net loss attributable to common shareholders of $ (666,192 ).
Third-quarter revenue and net loss improved substantially versus the prior-year quarter, supported by license revenue, while the company remains loss-making, nine-month research and development expense increased, and development progress depends on clinical execution, resource prioritization and potential partnerships.
Key metrics
as reported| Metric | Value | q/q | y/y |
|---|---|---|---|
| Three Months Ended September 30, 2026 License revenueGAAP | $ 2,100,000 | – | – |
| Three Months Ended September 30, 2026 Royalty revenueGAAP | $ 190,072 | – | – |
| Three Months Ended September 30, 2026 Total revenuesGAAP | $ 2,290,072 | – | – |
| Three Months Ended September 30, 2026 Research and development expenseGAAP | $ 2,070,033 | – | – |
| Three Months Ended September 30, 2026 General and administrative expenseGAAP | $ 1,088,564 | – | – |
| Three Months Ended September 30, 2026 Total operating expensesGAAP | $ 3,158,597 | – | – |
| Three Months Ended September 30, 2026 Operating lossGAAP | $ (868,525 ) | – | – |
| Three Months Ended September 30, 2026 Interest and investment incomeGAAP | $ 202,333 | – | – |
| Three Months Ended September 30, 2026 Total other incomeGAAP | $ 202,333 | – | – |
| Three Months Ended September 30, 2026 Loss before income tax expenseGAAP | $ (666,192 ) | – | – |
| Three Months Ended September 30, 2026 Income tax expenseGAAP | - | – | – |
| Three Months Ended September 30, 2026 Net loss attributable to common shareholdersGAAP | $ (666,192 ) | – | – |
| Three Months Ended September 30, 2026 Basic loss per share attributable to common stockGAAP | $ (0.08 ) | – | – |
| Three Months Ended September 30, 2026 Diluted loss per share attributable to common stockGAAP | $ (0.08 ) | – | – |
| Three Months Ended September 30, 2026 Weighted average common shares outstanding, basicGAAP | 8,244,542 | – | – |
| Three Months Ended September 30, 2026 Weighted average common shares outstanding, dilutedGAAP | 8,244,542 | – | – |
| Three Months Ended September 30, 2026 Comprehensive lossGAAP | $ (679,350 ) | – | – |
| Nine Months Ended September 30, 2026 License revenueGAAP | $ 2,100,000 | – | – |
| Nine Months Ended September 30, 2026 Royalty revenueGAAP | $ 499,568 | – | – |
| Nine Months Ended September 30, 2026 Total revenuesGAAP | $ 2,599,568 | – | – |
| Nine Months Ended September 30, 2026 Research and development expenseGAAP | $ 6,875,816 | – | – |
| Nine Months Ended September 30, 2026 General and administrative expenseGAAP | $ 3,283,987 | – | – |
| Nine Months Ended September 30, 2026 Total operating expensesGAAP | $ 10,159,803 | – | – |
| Nine Months Ended September 30, 2026 Operating lossGAAP | $ (7,560,235 ) | – | – |
| Nine Months Ended September 30, 2026 Interest and investment incomeGAAP | $ 599,754 | – | – |
| Nine Months Ended September 30, 2026 Total other incomeGAAP | $ 599,754 | – | – |
| Nine Months Ended September 30, 2026 Loss before income tax expenseGAAP | $ (6,960,481 ) | – | – |
| Nine Months Ended September 30, 2026 Income tax expenseGAAP | $ (200 ) | – | – |
| Nine Months Ended September 30, 2026 Net loss attributable to common shareholdersGAAP | $ (6,960,681 ) | – | – |
| Nine Months Ended September 30, 2026 Basic loss per share attributable to common stockGAAP | $ (0.90 ) | – | – |
| Nine Months Ended September 30, 2026 Diluted loss per share attributable to common stockGAAP | $ (0.90 ) | – | – |
| Nine Months Ended September 30, 2026 Weighted average common shares outstanding, basicGAAP | 7,757,487 | – | – |
| Nine Months Ended September 30, 2026 Weighted average common shares outstanding, dilutedGAAP | 7,757,487 | – | – |
| Nine Months Ended September 30, 2026 Comprehensive lossGAAP | $ (6,991,685 ) | – | – |
What drove it
- Third-quarter revenue consisted of license and collaboration revenue of $2.1 million and royalty revenue from TLANDO sales of $190,000.
- The decrease in third-quarter research and development expense primarily reflected lower costs related to the LPCN 2401 study, which was placed on hold in 2025, and lower LPCN 1154 clinical costs compared with costs incurred for the prior Phase 3 study during the third quarter of 2025, partially offset by higher personnel costs.
- The increase in third-quarter general and administrative expense primarily reflected higher personnel costs and higher legal fees related to protecting intellectual property and promoting corporate strategy.
- Lipocine initiated the BLOOM Phase 3 placebo-controlled outpatient study of LPCN 1154 for postpartum depression in September 2026. The study is expected to enroll approximately 120 participants.
- Health Canada approved TLANDO in September 2026, and Verity Pharma is planning for launch in Canada in early 2027.
- Pharmalink received product marketing authorization approval for TESTYRA in the United Arab Emirates in July 2026 and is planning for launch in the UAE in early 2027.
Concerns
- Lipocine reported a net loss attributable to common shareholders of $ (666,192 ) for the third quarter and $ (6,960,681 ) for the nine months ended September 30, 2026.
- Nine-month research and development expense was $ 6,875,816, compared with $ 5,906,118 for the prior-year period, driven by higher costs related to LPCN 1154 studies and other clinical trial costs, as well as higher personnel expense.
- Future studies of LPCN 2201 and LPCN 2203 are subject to resource prioritization.
- The FDA feedback indicated that the LPCN 1154 NDA submission package appears complete for a 505(b)(2) NDA submission except for the need for a single positive and well-controlled Phase 3 trial.
- Lipocine continues to explore business partnerships for development, approval and commercialization of BRLIZIO and for TLANDO in certain territories.
What to watch
- Enrollment, efficacy and safety results from the BLOOM Phase 3 study of LPCN 1154.
- The timing and execution of planned TLANDO launches in Canada and the United Arab Emirates in early 2027.
- Additional TLANDO royalty revenue and potential licensing or collaboration revenue.
- FDA protocol submissions and potential Phase 2 studies for LPCN 2201 and LPCN 2203.
- Cash resources, clinical-study expenditures and potential strategic partnerships.
Balance sheet and cash flow
- Unrestricted cash, cash equivalents and marketable investment securities were $21.5 million as of September 30, 2026, compared to $14.9 million at December 31, 2025.
- Unrestricted cash, cash equivalents and marketable investment securities were approximately $28.5 million as of November 4, 2026 (unaudited).
- Cash and cash equivalents were $ 2,594,151 as of September 30, 2026, compared to $ 5,205,842 as of December 31, 2025.
- Marketable investment securities were $ 18,861,297 as of September 30, 2026, compared to $ 9,724,545 as of December 31, 2025.
- Total current assets were $ 23,112,657 as of September 30, 2026, compared to $ 16,877,566 as of December 31, 2025.
- Total assets were $ 23,196,594 as of September 30, 2026, compared to $ 17,005,612 as of December 31, 2025.
- Total current liabilities were $ 2,034,446 as of September 30, 2026, compared to $ 2,528,196 as of December 31, 2025.
- Total liabilities were $ 2,034,446 as of September 30, 2026, compared to $ 2,528,196 as of December 31, 2025.
- Total stockholders’ equity was $ 21,162,148 as of September 30, 2026, compared to $ 14,477,416 as of December 31, 2025.
Analysis
Lipocine’s third-quarter revenue was $ 2,290,072, compared with $ 114,574 in the prior-year quarter. The period included $ 2,100,000 of license revenue and $ 190,072 of royalty revenue. The prior-year third quarter had no license revenue and its revenue consisted entirely of TLANDO royalties, making license activity the principal reported driver of the quarter’s higher revenue base.
Third-quarter operating expense was $ 3,158,597, compared with $ 3,475,614 in the prior-year quarter. Research and development expense was $ 2,070,033 versus $ 2,707,777, while general and administrative expense increased to $ 1,088,564 from $ 767,837. Management attributed the R&D reduction principally to lower LPCN 2401 and LPCN 1154 clinical costs, partly offset by personnel costs, while the G&A increase reflected personnel and intellectual-property-related legal costs.
The company reported an operating loss of $ (868,525 ) and net loss attributable to common shareholders of $ (666,192 ), or $ (0.08 ) per diluted share, for the third quarter. For the nine months, net loss attributable to common shareholders was $ (6,960,681 ), or $ (0.90 ) per diluted share, compared with $ (7,257,421 ), or $ (1.35 ) per diluted share, in the prior-year period. Nine-month R&D expense increased to $ 6,875,816 as LPCN 1154 studies, other clinical trial costs and personnel expense rose.
Liquidity was $21.5 million of unrestricted cash, cash equivalents and marketable investment securities at September 30, 2026, and approximately $28.5 million as of November 4, 2026, unaudited. The key development event was September initiation of the BLOOM Phase 3 study for LPCN 1154 in postpartum depression. FDA feedback identified a single positive and well-controlled Phase 3 trial as the remaining requirement described for a potential 505(b)(2) NDA submission. Commercially, the company cited planned early-2027 launches for TLANDO in Canada and TESTYRA in the UAE, while continuing to seek partnerships.
Not in the filing
stated, not guessed- Gross profit and gross margin
- Operating cash flow
- Free cash flow
- Debt balances
- Share repurchases
- Dividends
- Financial guidance for revenue, operating expenses, gross margin or tax rate
- Prior-quarter comparisons
- Reported year-over-year percentage changes
- Named executive quotes
Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. Guided figures in the outlook comparison come from the company’s previous release. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.